12:00 AM
Feb 02, 2012
 |  BC Innovations  |  Distillery Therapeutics


Indication Target/marker/pathway Summary Licensing status Publication and contact information
Bladder cancer Keratin 14 (KRT14) Patient sample studies suggest KRT14 could help predict bladder cancer prognosis. In two sets of gene and protein expression data from bladder cancer patient samples, KRT14 expression correlated with lower overall survival. Next steps include testing whether KRT14 can predict patient response to chemotherapy. SciBX 5(5); doi:10.1038/scibx.2012.118 Published online Feb. 2, 2012 Patent application filed; available for licensing Volkmer, J.-P. et al. Proc. Natl. Acad. Sci. USA; published online Jan. 19, 2012; doi:10.1073/pnas.1120605109 Contact: Keith S. Chan, Baylor College of Medicine, Houston, Texas e-mail: kc1@bcm.edu Contact: Irving L. Weissman, Stanford University, Stanford, Calif. e-mail: irv@stanford.edu Contact: Debashis Sahoo, same affiliation as above e-mail: sahoo@stanford.edu
Breast cancer IL-20 Studies in mice and in human samples suggest inhibiting IL-20 could help treat breast cancer and breast cancer-induced bone loss. In primary breast tumor samples, levels of IL-20 were inversely correlated with metastasis-free survival. In mice with mammary tumors, an anti-IL-20 antibody lowered tumor growth compared with control IgG. In mouse models of metastatic mammary cancer, the antibody decreased both the number of bone metastases and bone loss compared with control IgG. Ongoing work includes testing IL-20 inhibition in animal models of bone metastases of prostate and other cancers. NN8226 (anti-IL20), an anti-IL-20 mAb from Novo Nordisk A/S, is in Phase II testing to treat rheumatoid arthritis (RA). SciBX 5(5); doi:10.1038/scibx.2012.119 Published online Feb. 2, 2012 Patented by National Cheng Kung University; available for licensing Hsu, Y.-H. et al. J. Immunol.; published online Jan. 11, 2012; doi:10.4049/jimmunol.1102843 Contact: Ming-Shi Chang, National Cheng Kung University, Tainan, Taiwan e-mail: mschang@mail.ncku.edu.tw
Cancer Lymphocyte-activation gene 3 (LAG3; CD223); PD-1 receptor (PDCD1; PD-1; CD279) Mouse studies suggest inhibiting both LAG3 and PD-1 could help treat cancer. In two mouse models of cancer, combined injection of anti-Lag3 and anti-Pd-1 antibodies increased the number of tumor-free animals compared with injection of either antibody alone. Next steps could include screening additional cancer types for responsiveness to the combination antibody therapy. At least six companies have antibodies or fusion proteins that target LAG3 or PD-1 in Phase II testing or earlier to treat cancer. SciBX 5(5); doi:10.1038/scibx.2012.120 Published online Feb. 2, 2012 Patents pending; licensing status unavailable Woo, S.-R. et al. Cancer Res.; published online Dec. 20, 2011; doi:10.1158/0008-5472.CAN-11-1620 Contact: Dario A.A. Vignali, St. Jude Children's Research Hospital, Memphis, Tenn. e-mail: dario.vignali@stjude.org
Melanoma Wingless-type MMTV integration site family member 3A (WNT3A); BRAF Mouse studies suggest activating WNT signaling may increase the efficacy of BRAF inhibitors in melanoma. In a xenograft mouse model of melanoma, a BRAF inhibitor plus transplantation of cells overexpressing WNT3A led to less tumor growth than a BRAF inhibitor plus transplantation of cells expressing a control protein. Zelboraf vemurafenib, a BRAF inhibitor from Daiichi Sankyo Co. Ltd. and Roche, is marketed to treat metastatic melanoma. SciBX 5(5); doi:10.1038/scibx.2012.121 Published online Feb. 2, 2012 Patent applications filed; available for licensing Biechele, T.L. et al. Sci. Signal.; published online Jan. 10, 2012; doi:10.1126/scisignal.2002274 Contact: Andy J. Chien, University of Washington...

Read the full 2795 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >